Merck said on Thursday a combination treatment testing a new type of immunotherapy failed to significantly slow disease progression in lung cancer patients who did not respond to previous treatments.
Microbial diversity affects whether a tumor grows, leads to inflammation, develops immune escape mechanisms, or develops therapeutic resistance, said an internal medicine specialist.